Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Validation of an Algorithm for Predicting Awakenings Associated With Trauma-related Nightmares, Based on the Analysis of Physiological Patterns in Military and Former Military Patients Suffering From Post-traumatic Stress Disorder (CAUD-PIN)

28 de setembro de 2026 atualizado por: Direction Centrale du Service de Santé des Armées

The goal of this clinical trial is to validate an artificial intelligence algorithm called CAUD-PIN (CAUchemar Detection on INdividualized Parameters) to predict nightmare-related awakenings in military personnel and veterans suffering from post-traumatic stress disorder (PTSD). The main question it aim to answer is :

  • Can the CAUD-PIN algorithm detect physiological patterns preceding trauma-related nightmare awakenings with a sensitivity greater than 80%?
  • What physiological signals best predict the occurrence of a trauma-related nightmare awakening?

Participants will:

Wear two non-invasive devices at home - an EEG headband and a wrist-worn sensor bracelet - for 15 consecutive nights Press a button on the bracelet each time they wake up from a nightmare Complete sleep and daytime diaries every evening and morning Attend two clinical assessments (at enrollment and at the end of the study, one month later) at one of the three participating military hospitals

The algorithm will be applied to the recorded data after collection and does not intervene in real time or affect participants' standard medical care in any way.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

27

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Brest, França, 29200
        • Recrutamento
        • Clermont Tonnerre Regional Military Teaching Hospital, psychiatry department
        • Contato:
          • Julia SALOMÉ, MD, PHD
      • Clamart, França, 92190
        • Ainda não está recrutando
        • Percy National Military Teaching Hospital, Department of Psychiatry
        • Contato:
          • Gilles SIPAHIMALANI, MD, PhD
    • Île-de-France Region
      • Saint-Mandé, Île-de-France Region, França, 94160
        • Recrutamento
        • Bégin National Military Teaching Hospital
        • Contato:
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age between 18 and 65 years (age limit related to military status)
  • Active military personnel or veterans
  • Receiving psychiatric care in a military hospital (HNIA Bégin, HNIA Percy, or HRIA Brest) for PTSD related to combat trauma (exposure to death or life-threatening situations)
  • PCL-5 score > 33
  • Written informed consent obtained
  • Trauma-related nightmares occurring ≥ 4 times per week

Exclusion Criteria:

  • Pre-existing progressive psychiatric disorder prior to trauma (condition requiring long-term treatment > 1 year)
  • Sleep disorder affecting sleep architecture (obstructive sleep apnea syndrome, narcolepsy)
  • Neurological disorder (acute confusional state, severe traumatic brain injury) Inability to provide informed consent
  • Persons under legal protection measures (guardianship, curatorship, or equivalent judicial protection)
  • Persons not affiliated with a social security scheme

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: CAUD-PIN Validation Group

French Military personnel and/or veterans with PTSD wear two non-invasive wearable devices at home - an EEG headband (Hypnodyne Zmax Lite) and a multisensor bracelet (Empatica EmbracePlus) - for 15 consecutive nights. Participants press a button on the bracelet to report each nightmare-related awakening. Physiological data are analyzed post-hoc by the CAUD-PIN algorithm to validate its ability to predict trauma-related nightmare awakenings. Two clinical assessments are conducted at enrollment and at study completion.

CAUD-PIN (CAUchemar Detection on INdividualized Parameters) is a non-invasive, AI-based predictive algorithm developed by the VIFASOM research team (UMR 7330, Université Paris Cité / French Military Health Service) from the SOMMEPT clinical project. It analyzes multimodal physiological signals recorded during home sleep to identify patterns preceding Trauma-related nightmare awakenings in military patients with PTSD. Data are collected using two wearable devices: an EEG headband (Hypnodyne Zmax Lite) measuring brain activity and sleep stages, and a wrist-worn multisensor bracelet (Empatica EmbracePlus) measuring heart rate, electrodermal activity, skin temperature, and motor activity. The algorithm is applied exclusively post-hoc to pseudonymized recordings, with no real-time intervention and no impact on participants' standard medical care.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Sensitivity of the CAUD-PIN algorithm in predicting Trauma-related nightmare awakenings
Prazo: During the 15 consecutive nights of home sleep recording

Sensitivity will be calculated as the number of Trauma-related nightmare awakenings correctly identified by the CAUD-PIN algorithm divided by the total number of confirmed trauma-related nightmare awakenings, multiplied by 100.

Unit of Measure: Percentage

During the 15 consecutive nights of home sleep recording

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Specificity of the CAUD-PIN algorithm for predicting Trauma-related nightmare awakenings
Prazo: During the 15 consecutive nights of home sleep recording

Specificity will be calculated as the number of events correctly classified as not being trauma-related nightmare awakenings divided by the total number of confirmed non-nightmare events, multiplied by 100.

Unit of Measure: Percentage

During the 15 consecutive nights of home sleep recording
Positive predictive value of the CAUD-PIN algorithm
Prazo: During the 15 consecutive nights of home sleep recording

Positive predictive value will be calculated as the number of correctly predicted trauma-related nightmare awakenings divided by the total number of trauma-related nightmare awakenings predicted by the CAUD-PIN algorithm, multiplied by 100.

Unit of Measure: Percentage

During the 15 consecutive nights of home sleep recording
Negative predictive value of the CAUD-PIN algorithm
Prazo: During the 15 consecutive nights of home sleep recording

Negative predictive value will be calculated as the number of events correctly predicted as not being trauma-related nightmare awakenings divided by the total number of events predicted as not being trauma-related nightmare awakenings, multiplied by 100.

Unit of Measure: Percentage

During the 15 consecutive nights of home sleep recording
Prediction lead time before trauma-related nightmare awakening
Prazo: Through 15 nights of recording

Mean time (in seconds) between the physiological predictive pattern detected by the CAUD-PIN algorithm and the participant's button press indicating a trauma-related nightmare awakening.

Unit of Measure: Seconds

Through 15 nights of recording
Intra- and inter-individual variability in heart rate preceding trauma-related nightmare awakenings
Prazo: During the 15 consecutive nights of home sleep recording

Intra- and inter-individual variability in heart rate (beats per minute, bpm) preceding trauma-related nightmare awakenings.

Variability will be quantified using:

  • Within-subject standard deviation (SD)
  • Between-subject variance estimated using mixed-effects models
During the 15 consecutive nights of home sleep recording
Intra- and inter-individual variability in electrodermal activity preceding trauma-related nightmare awakenings
Prazo: After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)

Intra- and inter-individual variability in electrodermal activity (microsiemens, µS) preceding trauma-related nightmare awakenings.

Variability will be quantified using:

  • Within-subject standard deviation (SD)
  • Between-subject variance estimated using mixed-effects models
After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)
Intra- and inter-individual variability in skin temperature preceding trauma-related nightmare awakenings
Prazo: After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)

Intra- and inter-individual variability in skin temperature (°C) preceding trauma-related nightmare awakenings.

Variability will be quantified using:

  • Within-subject standard deviation (SD)
  • Between-subject variance estimated using mixed-effects models
After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)
Intra- and inter-individual variability in motor activity preceding trauma-related nightmare awakenings
Prazo: After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)

Intra- and inter-individual variability in motor activity (activity counts) preceding trauma-related nightmare awakenings.

Variability will be quantified using:

  • Within-subject standard deviation (SD)
  • Between-subject variance estimated using mixed-effects models
After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)
Area Under the Curve (AUC) of the CAUD-PIN algorithm on combined dataset
Prazo: After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)

Area Under the Receiver Operating Characteristic Curve (AUC, unitless) of the CAUD-PIN algorithm when trained and evaluated on the CAUD-PIN dataset alone compared to the combined dataset (SOMMEPT + CAUD-PIN).

After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)
F1-score of the CAUD-PIN algorithm on combined dataset
Prazo: After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)

F1-score (unitless) of the CAUD-PIN algorithm when trained and evaluated on the CAUD-PIN dataset alone compared to the combined dataset (SOMMEPT + CAUD-PIN).

After completion of all participant data collection, following the 15-night recording period for each participant (approximately 18 months after study start)
Correlation between PCL-5 total score and percentage of trauma-related nightmare nights
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

PTSD severity will be assessed at T1 using the PTSD Checklist for DSM-5 (PCL-5) total score, ranging from 0 to 80 points. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Beck Depression Inventory total score and percentage of trauma-related nightmare nights
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Depression severity will be assessed at T1 using the Beck Depression Inventory (BDI) total score, ranging from 0 to 63 points. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between WHOQOL-BREF score and percentage of trauma-related nightmare nights
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Quality of life will be assessed at T1 using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) [specify total or domain score and range]. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Nightmare Severity Index score and percentage of trauma-related nightmare nights
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Nightmare severity will be assessed at T1 using the Nightmare Severity Index (NSI) total score. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between mean number of trauma-related nightmare awakenings per night and percentage of trauma-related nightmare nights
Prazo: During the 15 consecutive nights of home sleep recording

The mean number of trauma-related nightmare awakenings per night will be calculated as the total number of participant-confirmed trauma-related nightmare awakenings divided by the number of valid recording nights. The percentage of trauma-related nightmare nights will be calculated as the percentage of valid recording nights containing at least one confirmed awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

During the 15 consecutive nights of home sleep recording
Correlation between mean heart rate and percentage of trauma-related nightmare nights
Prazo: During the 15 consecutive nights of home sleep recording

Heart rate will be measured in beats per minute using Empatica EmbracePLUS. For each participant, mean heart rate will be calculated across sleep period preceeding trauma-ralated awakeking across 15 nights. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

During the 15 consecutive nights of home sleep recording
Correlation between mean electrodermal activity and percentage of trauma-related nightmare nights
Prazo: During the 15 consecutive nights of home sleep recording

Electrodermal activity will be measured in microsiemens (µS) using Empatica EmbracePLUS. For each participant, mean electrodermal activity will be calculated across across sleep period preceeding trauma-ralated awakeking across across sleep period preceeding trauma-ralated awakeking across 15 nights. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

During the 15 consecutive nights of home sleep recording
Correlation between mean skin temperature and percentage of trauma-related nightmare nights
Prazo: During the 15 consecutive nights of home sleep recording

Skin temperature will be measured in degrees Celsius using Empatica EmbracePLUS. For each participant, mean skin temperature will be calculated across across sleep period preceeding trauma-ralated awakeking across 15 nights. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

During the 15 consecutive nights of home sleep recording
Correlation between mean motor activity and percentage of trauma-related nightmare nights
Prazo: During the 15 consecutive nights of home sleep recording

Motor activity will be measured in activity counts using Empatica EmbracePLUS. For each participant, mean motor activity will be calculated across across sleep period preceeding trauma-ralated awakeking across 15 nights. Trauma-related nightmare frequency will be calculated as the percentage of valid recording nights containing at least one participant-confirmed trauma-related nightmare awakening. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

During the 15 consecutive nights of home sleep recording
Correlation between trauma-related nightmare awakening frequency and change in PCL-5 total score between T1 and T2
Prazo: From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)

Trauma-related nightmare frequency will be calculated as the total number of participant-confirmed trauma-related nightmare awakenings divided by the number of valid recording nights, expressed as awakenings per night. PTSD severity will be assessed at T1 and T2 using the PCL-5 total score, ranging from 0 to 80 points. Change will be calculated as the difference between the PCL-5 total scores obtained at T1 and T2. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)
Correlation between trauma-related nightmare awakening frequency and change in Beck Depression Inventory total score between T1 and T2
Prazo: From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)

Trauma-related nightmare frequency will be calculated as the total number of participant-confirmed trauma-related nightmare awakenings divided by the number of valid recording nights, expressed as awakenings per night. Depression severity will be assessed at T1 and T2 using the Beck Depression Inventory total score, ranging from 0 to 63 points. Change will be calculated as the difference between the BDI total scores obtained at T1 and T2. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)
Correlation between trauma-related nightmare awakening frequency and change in WHOQOL-BREF score between T1 and T2
Prazo: From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)

Trauma-related nightmare frequency will be calculated as the total number of participant-confirmed trauma-related nightmare awakenings divided by the number of valid recording nights, expressed as awakenings per night. Quality of life will be assessed at T1 and T2 using the WHOQOL-BREF [specify total or domain score and range]. Change will be calculated as the difference between the WHOQOL-BREF scores obtained at T1 and T2. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

From Visit 1 (baseline) to Visit 2 (end of study, Day 30 ± 5 days after inclusion)
Correlation between PCL-5 total score at T1 and PSQI total score
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

PTSD severity will be assessed at T1 using the PCL-5 total score, ranging from 0 to 80 points. Subjective sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) total score, ranging from 0 to 21 points, with higher scores indicating poorer sleep quality. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between PCL-5 total score at T1 and mean total sleep time
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

PTSD severity will be assessed at T1 using the PCL-5 total score, ranging from 0 to 80 points. Total sleep time will be measured in minutes usingHypnodyne Zmax Lite device and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between PCL-5 total score at T1 and mean sleep efficiency
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

PTSD severity will be assessed at T1 using the PCL-5 total score, ranging from 0 to 80 points. Sleep efficiency will be measured usingHypnodyne Zmax Lite device and PSQI questionnary, calculated as total sleep time divided by time in bed and multiplied by 100, and averaged across valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between PCL-5 total score at T1 and mean wake after sleep onset
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

PTSD severity will be assessed at T1 using the PCL-5 total score, ranging from 0 to 80 points. Wake after sleep onset will be measured in minutes using Hypnodyne Zmax Lite device and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Beck Depression Inventory total score at T1 and PSQI total score
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Depression severity will be assessed at T1 using the Beck Depression Inventory total score, ranging from 0 to 63 points. Subjective sleep quality will be assessed using the PSQI total score, ranging from 0 to 21 points, with higher scores indicating poorer sleep quality. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Beck Depression Inventory total score at T1 and mean total sleep time
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Depression severity will be assessed at T1 using the Beck Depression Inventory total score, ranging from 0 to 63 points. Total sleep time will be measured in minutes using Hypnodyne Zmax Lite device and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Beck Depression Inventory total score at T1 and mean sleep efficiency
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Depression severity will be assessed at T1 using the Beck Depression Inventory total score, ranging from 0 to 63 points. Sleep efficiency will be measured using Hypnodyne Zmax Lite device and PSQI questionnary, calculated as total sleep time divided by time in bed and multiplied by 100, and averaged across valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Beck Depression Inventory total score at T1 and mean wake after sleep onset
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Depression severity will be assessed at T1 using the Beck Depression Inventory total score, ranging from 0 to 63 points. Wake after sleep onset will be measured in minutes using using Hypnodyne Zmax Lite device and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Nightmare Severity Index score at T1 and PSQI total score
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Nightmare severity will be assessed at T1 using the Nightmare Severity Index total score.. Subjective sleep quality will be assessed using the PSQI total score, ranging from 0 to 21 points, with higher scores indicating poorer sleep quality. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Nightmare Severity Index score at T1 and mean total sleep time
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Nightmare severity will be assessed at T1 using the Nightmare Severity Index total score.. Total sleep time will be measured in minutes using Hypnodyne Zmax Lite and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Nightmare Severity Index score at T1 and mean sleep efficiency
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Nightmare severity will be assessed at T1 using the Nightmare Severity Index total score.. Sleep efficiency will be measured using Hypnodyne Zmax Lite and PSQI questionnary, calculated as total sleep time divided by time in bed and multiplied by 100, and averaged across valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording
Correlation between Nightmare Severity Index score at T1 and mean wake after sleep onset
Prazo: At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Nightmare severity will be assessed at T1 using the Nightmare Severity Index total score.. Wake after sleep onset will be measured in minutes using Hypnodyne Zmax Lite and PSQI questionnary and averaged across all valid recording nights. A single Pearson or Spearman correlation coefficient will be reported. Unit of Measure: Correlation coefficient (r).

At Visit 1 (baseline) and during the 15 consecutive nights of home sleep recording

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Emeric SAGUIN, MD, PhD, Department of Psychiatry, Begin National Military Teaching Hospital, Saint-Mandé, 94160, France

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de abril de 2026

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

1 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

2 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de setembro de 2026

Primeira postagem (Real)

1 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de setembro de 2026

Última verificação

1 de março de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared. This study involves military personnel and veterans with PTSD, whose physiological and psychological data are considered highly sensitive. Data are pseudonymized and managed in accordance with the French General Data Protection Regulation (GDPR, EU 2016/679) and the Reference Methodology MR-001. Access is restricted to authorized members of the research team. Only aggregated and de-identified results will be disseminated through scientific publications and conference presentations.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever